Boston Scientific (BSX) Revenue & Quarterly History
Explore Boston Scientific Corporation (BSX) revenue from 2023 through the latest reported quarter, with SEC-sourced comparisons and filing-constrained analysis.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue increased compared to the same quarter last year, driven by innovation and commercial execution across several business units. However, revenue declined from the immediately preceding quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$5.2B
Revenue reported for this quarter.
Quarter-over-quarter
-1.6%
Change from the immediately preceding quarter.
Year-over-year
+11.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$20.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $5.1B | +22.8% |
| Sep 30, 2025 | $5.1B | +20.3% |
| Dec 31, 2025 | $5.3B | +15.9% |
| Mar 31, 2026 | $5.2B | +11.6% |
Revenue performance
The company reported higher net sales year over year, with the increase attributed to strong performance in Electrophysiology and Interventional Cardiology and Vascular Therapies.
Quarterly comparison
Compared to the prior quarter, revenue was lower, while compared to the same period a year ago, revenue was higher.
What to watch
The company noted that foreign currency fluctuations had a negative impact on reported growth.